Karyopharm Therapeutics Inc. entered into a private placement with RA Capital Management on March 24, 2026, issuing securities for gross proceeds of approximately $30 million, and separately sold shares under an existing market agreement for net proceeds of approximately $19.8 million. The company stated its existing liquidity, including these proceeds, is expected to fund its current operating plans into late in the third quarter of 2026.
Key takeaways
Entered into a Securities Purchase Agreement with RA Capital Management on March 24, 2026.
Issued 1,030,354 shares of common stock at $6.785 per share and pre-funded warrants for up to 3,391,164 shares at $6.7849 per warrant.
Issued accompanying warrants to purchase 4,421,518 shares of common stock with a $10.00 per share exercise price.
The private placement closed on March 26, 2026, generating gross proceeds of approximately $30 million.
Sold an aggregate of 2,994,441 shares of common stock under an Open Market Sale Agreement with Jefferies LLC for net proceeds of approximately $19.8 million.
Following these transactions, the company will have 22,543,316 shares of common stock outstanding and pre-funded warrants to purchase 4,005,556 shares outstanding.